Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors by Daiki Murata, Koichi Azuma, Kenta Murotani, Yoshiaki Zaizen, Tomoaki Hoshino

Get full text

Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developin... by Akihiko Kawahara, Tetsuro Sasada, Koichi Azuma, Hidenobu Ishii, Norikazu Matsuo, Takaaki Tokito, Tomoaki Hoshino, Yohei Miyagi, Huihui Xiang, Tomoyuki Tagami, Rika Kasajima, Yumiko Kato, Sachise Karakawa, Shinya Kikuchi, Akira Imaizumi, Kenta Murotani

Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

Get full text

Turtle Study: A Phase 2 Study of Durvalumab Plus Carboplatin and Etoposide in Elderly Patients With Extensive-Stage SCLC (LOGiK 2003) by Hidenobu Ishii, MD, PhD, Koichi Azuma, MD, PhD, Yuta Yamanaka, MD, Hiroshige Yoshioka, MD, PhD, Yukihiro Toi, MD, Naoki Shingu, MD, Katsuhiko Naoki, MD, PhD, Masaki Okamoto, MD, PhD, Yuko Tsuchiya-Kawano, MD, PhD, Taishi Harada, MD, Hiroyuki Inoue, MD, PhD, Hiroshi Ishii, MD, PhD, Kazunori Tobino, MD, PhD, Chiho Nakashima, MD, PhD, Yoshifusa Koreeda, MD, Yasushi Hisamatsu, MD, Shinsuke Tsumura, MD, Takashi Inagaki, MD, Keiko Mizuno, MD, PhD, Takayuki Shimose, MMath, Isamu Okamoto, MD, PhD

Get full text